Abstract
The global therapeutic botulinum toxin (BTX) market, including the US, Europe
(France, Germany, Italy, Spain, and the UK), and Japan, exceeded $600 million
in 2008
Through 2013, growth will be fueled by the approval of new treatment
indications of BTX, which will significantly expand procedure volumes and
bolster unit demand
View Cart
